



ACTIVATED LIPID ENDOCANNABINOID SIGNALING IN ATHEROSCLEROSIS: DRIVING FORCE OR PROTECTIVE MECHANISM?


GUEST LECTURE by




Prof. Dr. Sabine Steffens
Institute of Cardiovascular Prevention, University Hospital, University of Munich, Germany

Monday, 13.10.2014
17:00

HS 07.03, Preclinics
Harrachgasse 21, MUG




CB₁ antagonism inhibits accelerated neointima formation in FAAH-deficient mice.



Fatty acid amide hydrolase (FAAH) deficiency affects plaque quality.


Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice. Lenglet et al. (2013) *Arterioscler Thromb Vasc Biol* 33:215-23



CB₁ antagonism inhibits accelerated neointima formation in ApoE^{-/-} mice.

Endogenous cannabinoid receptor CB₁ activation promotes vascular smooth-muscle cell proliferation and neointima formation. Molica et al. (2013) *J Lipid Res* 54:1360-8

Myocardial infarction



Potential therapeutic targets of CB₂ activation in cardiovascular disorders.

Targeting cannabinoid receptor CB₂ in cardiovascular disorders: promises and controversies. Steffens & Pacher (2012) *Brit J Pharmacol* 167:313-23